Acute, severe and anaphylactoid reactions are very rare with low-molecular-weight iron dextran, CosmoFer(R)

Vaage-Nilsen, Odd

doi:10.1093/ndt/gfn251

Cited by 6 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since its European launch in 2001, CosmoFer has been increasingly used. The CosmoFer SmPC (Summary of Product Characteristics), published in June 2007, concludes that ana‐phylactoid reactions are less than 1 in 10 000 (Vaage‐Nilsen 2008). Furthermore, administration of low‐molecular‐weight iron dextran as a TDI regimen has also been approved by the UK National Institute of Health and Clinical Excellence (National Collaborating Centre for Chronic Conditions 2006).…”

Section: Introductionmentioning

confidence: 99%

Comparison of Intravenous Iron Sucrose Versus Low‐molecular‐weight Iron Dextran in Chronic Kidney Disease

Sinha

Chiu

Peebles

et al. 2009

Journal of Renal Care

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison of Intravenous Iron Sucrose Versus Low‐molecular‐weight Iron Dextran in Chronic Kidney Disease

Sinha

Chiu

Peebles

et al. 2009

Journal of Renal Care

View full text Add to dashboard Cite

show abstract

“…The dextran used for particle covering is the same substance used for ferucarbotran. Although the present study suggested that the use of CMEADM is safe, in rare instances, dextran has been reported to elicit severe anaphylactic reactions (20). Consequently, the safety of CMEADM requires further elucidation.…”

Section: A B C Dmentioning

confidence: 59%

A novel blood-pooling MR contrast agent: Carboxymethyl-diethylaminoethyl dextran magnetite

Sonoda

Nitta

Tsuchiya

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

Gadofosveset trisodium is available as a prolonged pooling vascular contrast agent for magnetic resonance imaging. As gadolinium (Gd)-based agents may increase the risk for nephrogenic systemic fibrosis in patients with severe renal insufficiency, the present study synthesized carboxymethyl-diethylaminoethyl dextran magnetite (CMEADM) particles as a blood-pooling, non-Gd‑based contrast agent. CMEADM particles carry a negative or positive charge due to the binding of amino and carboxyl groups to the hydroxyl group of dextran. The present study evaluated whether the degree of charge alters the blood‑pooling time. The evaluation was performed by injecting four groups of three Japanese white rabbits each with CMEADM‑, CMEADM2‑, CMEADM+ (surface charges: ‑10.4, ‑41.0 and +9.6 mV, respectively) or with ultrasmall superparamagnetic iron oxide (USPIO; ‑11.5 mV). The relative signal intensity (SIrel) of each was calculated using the following formula: SIrel = (SI post‑contrast ‑ SI pre‑contrast / SI pre‑contrast) x 100. Following injection with the CMEADMs, but not with USPIO, the in vivo pooling time was prolonged to >300 min. No significant differences were attributable to the electric charge among the CMEADM‑, CMEADM2‑ or and CMEADM+ particles when analyzed with analysis of variance and Tukey's HSD test. Taken together, all three differently‑charged CMEADM2 particles exhibited prolonged vascular enhancing effects, compared with the USPIO. The degree of charge of the contrast agents used in the present study did not result in alteration of the prolonged blood pooling time.

show abstract

“…При введении высокомолекулярного декстрана железа анафилактоидные реакции наблюдались в 0,6-2,3% случаев [7]. При применении низкомолекулярного декстрана железа количество анафилактоидных реакций значительно снизилось, и они регистрировались менее чем в 1 случае на 10 000 [8]. При использовании сахарозного комплекса железа анафилактоидные реакции наблюдались в 0,0046% случаев (17 случаев на 367 000 больных, или 0,46 случая на 10 000) [5].…”

Section: парентеральные препараты железаunclassified

Current Treatment Options for Anemia in Pregnant Women (Lecture)

Чернов

Tarasova²

2017

Medicinskij sovet

View full text Add to dashboard Cite

Anemia can be detected in women before pregnancy, during pregnancy, after childbirth, during lactation period, requiring the attention of doctors and clinical and laboratory monitoring. Iron deficiency anemia (IDA) is the most common anemia in pregnant women. Accurate diagnosis is needed, since there are other possible anemias (posthemorrhagic, folate deficiency, anemia of chronic diseases). Modern options of IDA treatment are include the use of oral iron preparations (in 90% of pregnant women), intravenous iron preparations (in 10% of pregnant women), erythropoiesis stimulating agents – ESA (in 2% of pregnant women), and red blood cell transfusions in severe cases (in 3% of pregnant women). The history of creation of intravenous iron complexes in the laboratory of C.F. Hausmann, as well as properties of various intravenous iron complex formulations in the historical aspect of their manufacturing process (ferric gluconate, iron dextran, iron sucrose, ferric carboxymaltose) and the negotiation of adverse events are described. Indications for the use of intravenous iron preparations are the following: severe IDA, ineffectiveness or intolerance of oral iron, the presence of gastric or duodenal ulcer or gastrointestinal surgery in the past, contraindications for red blood cell transfusions, use of ESA. The advantages of intravenous ferric carboxymaltose are the possibility to use the high dose of iron preparation (1000 mg, 1 time per week), no need for test dose, the possibility of intravenous administration in 15 minutes. High efficiency, good tolerability of ferric carboxymaltose in the treatment of IDA are shown. Pharmacoeconomic analysis showed the feasibility of administration of ferric carboxymaltose in comparison with the drug of previous generation (iron sucrose). The use of intravenous iron preparations in the treatment of IDA in pregnant women will allow to minimize red blood cell transfusions and to move to the stage of drug replacement therapy.

show abstract

Acute, severe and anaphylactoid reactions are very rare with low-molecular-weight iron dextran, CosmoFer(R)

Cited by 6 publications

References 6 publications

Comparison of Intravenous Iron Sucrose Versus Low‐molecular‐weight Iron Dextran in Chronic Kidney Disease

Comparison of Intravenous Iron Sucrose Versus Low‐molecular‐weight Iron Dextran in Chronic Kidney Disease

A novel blood-pooling MR contrast agent: Carboxymethyl-diethylaminoethyl dextran magnetite

Current Treatment Options for Anemia in Pregnant Women (Lecture)

Contact Info

Product

Resources

About